NEWS
Multistem – A Stable, Off-the Shelf Regenerative Medicine Has Demonstrated Promise in Treating Patients with Acute Respiratory Distress Syndrome or ARDS
| Cell Culture DISH

In this podcast, we talked with Dr. Gil Van Bokkelen, Chairman and CEO, Athersys about recent clinical breakthroughs in regenerative medicine and manufacturing challenges. We also discussed Multistem and how it has been demonstrated to help patients with ARDS (Acute Respiratory Distress Syndrome). I began our interview by asking Dr. Van Bokkelen how regenerative medicine […]

Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemic
| Seattle Times

Venture capital fundraising can be tough enough without the added challenges of a pandemic. Nonetheless, Seattle-based biotechnology company Athira Pharma has landed an impressive $85 million for an upcoming round of pivotal testing on its NDX-1017 drug that seeks to restore brain function in Alzheimer’s patients. The company’s courting of investors, most intense from February through April, […]

Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot
| Endpoints News

There haven’t been a lot of big venture rounds for biotech companies looking to run a Phase II study in Alzheimer’s. The field has been a disaster over the past decade. Amyloid didn’t pan out as a target — going down in a litany of Phase III failures — and is now making its last […]